2.6. Analysis.

Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post baseline), Outcome 6: PD motor impairment ‐ Rush Dyskinesia Rating Scale

Comparison 2: Exenatide vs no treatment (14 months (60.8 weeks) post baseline), Outcome 6: PD motor impairment ‐ Rush Dyskinesia Rating Scale